Siegel R.L. Miller K.D. Jemal A.

Cancer statistics, 2020.

CA Cancer J Clin. 70: 7-30Klein E.A. Ciezki J. Kupelian P.A. et al.

Outcomes for intermediate risk prostate cancer: are there advantages for surgery, external radiation, or brachytherapy?.

Urol Oncol. 27: 67-71Center M.M. Jemal A. Lortet-Tieulent J. et al.

International variation in prostate cancer incidence and mortality rates.

Eur Urol. 61: 1079-1092Hugosson J. Roobol M.J. Månsson M. et al.

A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer.

Eur Urol. 76: 43-51

Prostate-specific antigen screening: pro.

Curr Opin Urol. 20: 185-188

Dahm P, et al. in Therapies for clinically localized prostate cancer. Rockville (MD): 2020.

Teo M.Y. Rathkopf D.E. Kantoff P.

Treatment of advanced prostate cancer.

Annu Rev Med. 70: 479-499Chaturvedi A.P. Dehm S.M.

Androgen receptor dependence.

Adv Exp Med Biol. 1210: 333-350Scher H.I. Beer T.M. Higano C.S. et al.

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.

Lancet. 375: 1437-1446Chen Y. Sawyers C.L. Scher H.I.

Targeting the androgen receptor pathway in prostate cancer.

Curr Opin Pharmacol. 8: 440-448

Maximal androgen blockade for advanced prostate cancer. Best practice & research.

Clin Endocrinol Metab. 22: 331-340

Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer.

Clin Cancer Res. 15: 4792-4798Loblaw D.A. Virgo K.S. Nam R. et al.

Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline.

J Clin Oncol. 25: 1596-1605

Drug insight: role of the androgen receptor in the development and progression of prostate cancer.

Nat Clin Pract Oncol. 4: 236-244

Mechanisms mediating androgen receptor reactivation after castration.

Urol Oncol. 27: 36-41Antonarakis E.S. Armstrong A.J.

Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer.

Prostate Cancer Prostatic Dis. 14: 206-218

Prostate cancer in 2011: redefining the therapeutic landscape for CRPC.

Nat Rev Urol. 9: 63-64Mukherji D. Eichholz A. De Bono J.S.

Management of metastatic castration-resistant prostate cancer: recent advances.

Drugs. 72: 1011-1028Davies A.H. Beltran H. Zoubeidi A.

Cellular plasticity and the neuroendocrine phenotype in prostate cancer.

Nat Rev Urol. 15: 271-286Knudsen K.E. Penning T.M.

Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer.

Trends Endocrinol Metab. 21: 315-324Schiewer M.J. Augello M.A. Knudsen K.E.

The AR dependent cell cycle: mechanisms and cancer relevance.

Mol Cell Endocrinol. 352: 34-45Marshall C.H. Antonarakis E.S.

Emerging treatments for metastatic castration-resistant prostate cancer: Immunotherapy, PARP inhibitors, and PSMA-targeted approaches.

Cancer Treat Res Commun. 23: 100164Giri V.N. Hyatt C. Gomella L.G.

Germline testing for men with prostate cancer: navigating an expanding new world of genetic evaluation for precision therapy and precision management.

J Clin Oncol. 37: 1455-1459Cheng H. Powers J. Schaffer K. et al.

Practical methods for integrating genetic testing into clinical practice for advanced prostate cancer.

Am Soc Clin Oncol Educ Book. 38: 372-381Giri V.N. Knudsen K.E. Kelly W.K. et al.

Implementation of germline testing for prostate cancer: philadelphia prostate cancer consensus conference 2019.

J Clin Oncol. 38: 2798-2811Morgans A.K. Szymaniak B.M.

Genetically-informed treatment for advanced and metastatic prostate cancer.

Can J Urol. 26: 54-56Antonarakis E.S. Gomella L.G. Petrylak D.P.

When and how to use PARP inhibitors in prostate cancer: a systematic review of the literature with an update on on-going trials.

Eur Urol Oncol. 3: 594-611Mucci L.A. Hjelmborg J.B. Harris J.R. et al.

Familial risk and heritability of cancer among twins in nordic countries.

JAMA. 315: 68-76Robinson D. Van Allen E.M. Wu Y.M. et al.

Integrative clinical genomics of advanced prostate cancer.

Cell. 162: 454Pritchard C.C. Mateo J. Walsh M.F. et al.

Inherited DNA-repair gene mutations in men with metastatic prostate cancer.

N Engl J Med. 375: 443-453Mateo J. Carreira S. Sandhu S. et al.

DNA-repair defects and olaparib in metastatic prostate cancer.

N Engl J Med. 373: 1697-1708Sartor O. Yang S. Ledet E. et al.

Inherited DNA-repair gene mutations in African American men with prostate cancer.

Oncotarget. 11: 440-442Estebanez-Perpina E. Bevan C.L. McEwan I.J.

Eighty years of targeting androgen receptor activity in prostate cancer: the fight goes on.

Cancers (Basel). 13: 509Linja M.J. Savinainen K.J. Saramäki O.R. et al.

Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer.

Cancer Res. 61: 3550-3555Han G. Buchanan G. Ittmann M. et al.

Mutation of the androgen receptor causes oncogenic transformation of the prostate.

Proc Natl Acad Sci U S A. 102: 1151-1156Arora V.K. Schenkein E. Murali R. et al.

Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade.

Cell. 155: 1309-1322Paschalis A. Sharp A. Welti J.C. et al.

Alternative splicing in prostate cancer.

Nat Rev Clin Oncol. 15: 663-675Antonarakis E.S. Armstrong A.J. Dehm S.M. et al.

J. Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting.

Prostate Cancer Prostatic Dis. 19: 231-241Senapati D. Kumari S. Heemers H.V.

Androgen receptor co-regulation in prostate cancer.

Asian J Urol. 7: 219-232Dai C. Heemers H. Sharifi N.

Androgen Signaling in Prostate Cancer.

Cold Spring Harb Perspect Med. 7Burkhart D.L. Morel K.L. Sheahan A.V. et al.

The Role of RB in Prostate Cancer Progression.

Adv Exp Med Biol. 1210: 301-318Tan H.L. Sood A. Rahimi H.A. et al.

Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma.

Clin Cancer Res. 20: 890-903Chen W.S. Alshalalfa M. Zhao S.G. et al.

Novel RB1-loss transcriptomic signature is associated with poor clinical outcomes across cancer types.

Clin Cancer Res. 25: 4290-4299Sharma A. Comstock C.E. Knudsen E.S. et al.

Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells.

Cancer Res. 67: 6192-6203Sharma A. Yeow W.S. Ertel A. et al.

The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression.

J Clin Invest. 120: 4478-4492McNair C. Xu K. Mandigo A.C. et al.

Differential impact of RB status on E2F1 reprogramming in human cancer.

J Clin Invest. 128: 341-358Mu P. Zhang Z. Benelli M. et al.

SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer.

Science. 355: 84-88Ku S.Y. Rosario S. Wang Y. et al.

Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance.

Science. 355: 78-83Grabowska M.M. DeGraff D.J. Yu X. et al.

Mouse models of prostate cancer: picking the best model for the question.

Cancer Metastasis Rev. 33: 377-397Berman-Booty L.D. Knudsen K.E.

Models of neuroendocrine prostate cancer.

Endocr Relat Cancer. 22: R33-R49Hamid A.A. Gray K.P. Shaw G. et al.

Compound genomic alterations of TP53, PTEN, and RB1 tumor suppressors in localized and metastatic prostate cancer.

Eur Urol. 76: 89-97Chakraborty G. Armenia J. Mazzu Y.Z. et al.

Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression.

Clin Cancer Res. 26: 2047-2064Mandigo A.C. Knudsen K.E.

Double trouble: concomitant RB1 and BRCA2 depletion evokes aggressive phenotypes.

Clin Cancer Res. 26: 1784-1786Quintanal-Villalonga A. Chan J.M. Yu H.A. et al.

Lineage plasticity in cancer: a shared pathway of therapeutic resistance.

Nat Rev Clin Oncol. 17: 360-371

Clinical and biological features of neuroendocrine prostate cancer.

Curr Oncol Rep. 23: 15Beltran H. Hruszkewycz A. Scher H.I. et al.

The role of lineage plasticity in prostate cancer therapy resistance.

Clin Cancer Res. 25: 6916-6924Beltran H. Rickman D.S. Park K. et al.

Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.

Cancer Discov. 1: 487-495Aparicio A.M. Shen L. Tapia E.L. et al.

Combined tumor suppressor defects characterize clinically defined aggressive variant prostate cancers.

Clin Cancer Res. 22: 1520-1530Berchuck J.E. Viscuse P.V. Beltran H. et al.

Clinical considerations for the management of androgen indifferent prostate cancer.

Prostate Cancer Prostatic Dis. https://doi.org/10.1038/s41391-021-00332-5Dicken H. Hensley P.J. Kyprianou N.

Prostate tumor neuroendocrine differentiation via EMT: The road less traveled.

Asian J Urol. 6: 82-90Tiwari R. Manzar N. Ateeq B.

Dynamics of cellular plasticity in prostate cancer progression.

Front Mol Biosci. 7: 130Bishop J.L. Thaper D. Vahid S. et al.

The master neural transcription factor BRN2 is an androgen receptor-suppressed driver of neuroendocrine differentiation in prostate cancer.

Cancer Discov. 7: 54-71Dardenne E. Beltran H. Benelli M. et al.

N-Myc induces an EZH2-mediated transcriptional program driving neuroendocrine prostate cancer.

Cancer Cell. 30: 563-577Davies A. Zoubeidi A. Selth L.A.

The epigenetic and transcriptional landscape of neuroendocrine prostate cancer.

Endocr Relat Cancer. 27: R35-R50Akamatsu S. Wyatt A.W. Lin D. et al.

The placental gene PEG10 promotes progression of neuroendocrine prostate cancer.

Cell Rep. 12: 922-936Kim S. Thaper D. Bidnur S. et al.

PEG10 is associated with treatment-induced neuroendocrine prostate cancer.

J Mol Endocrinol. 63: 39-49Brennen W.N. Zhu Y. Coleman I.M. et al.

Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer.

JCI Insight. 6: 146827Beltran H. Oromendia C. Danila D.C. et al.

A phase II trial of the aurora kinase a inhibitor alisertib for patients with castration- resistant and neuroendocrine prostate cancer: efficacy and biomarkers.

Clin Cancer Res. 25: 43-51Zhang W. Liu B. Wu W. et al.

Targeting the MYCN-PARP-DNA damage response pathway in neuroendocrine prostate cancer.

Clin Cancer Res. 24: 696-707Kwon O.J. Zhang L. Jia D. et al.

De novo induction of lineage plasticity from human prostate luminal epithelial cells by activated AKT1 and c-Myc.

Oncogene. 39: 7142-7151Tiwari R. Manzar N. Bhatia V. et al.

Androgen deprivation upregulates SPINK1 expression and potentiates cellular plasticity in prostate cancer.

Nat Commun. 11: 384Yasumizu Y. Rajabi H. Jin C. et al.

MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer.

Nat Commun. 11: 338Quaglia F. Krishn S.R. Wang Y. et al.

Differential expression of alphaVbeta3 and alphaVbeta6 integrins in prostate cancer progression.

PLoS One. 16: e0244985Quaglia F. Krishn S.R. Daaboul G.G. et al.

Small extracellular vesicles modulated by alphaVbeta3 integrin induce neuroendocrine differentiation in recipient cancer cells.

J Extracell Vesicles. 9: 1761072

Post-transcriptional gene regulation by microrna-194 promotes neuroendocrine transdifferentiation in prostate cancer.

Cell Rep. 34: 108585Domingo-Domenech J. et al.

Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells.

Cancer Cell. 22: 373-388

A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer.

Cancer Cell. 27: 223-239

Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity.

Nat Commun. 11: 5549

Rare Germline pathogenic mutations of DNA repair genes are most strongly associated with grade group 5 prostate cancer.

Eur Urol Oncol. 3: 224-230

Genomic and clinicopathologic characterization of ATM-deficient prostate cancer.

Clin Cancer Res. 26: 4869-4881Isaacsson Velho P. et al.

Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer.

Prostate. 78: 401-407

Germline mutations in ATM and BRCA1/2 are associated with grade reclassification in men on active surveillance for prostate cancer.

Eur Urol. 75: 743-749

Rare germline genetic variants and risk of aggressive prostate cancer.

Int J Cancer. 147: 2142-2149

Germline sequencing DNA repair genes in 5,545 men with aggressive and non- aggressive prostate cancer.

J Natl Cancer Inst. https://doi.org/10.1093/jnci/djaa132

Rare germline variants in DNA repair genes and the angiogenesis pathway predispose prostate cancer patients to develop metastatic disease.

Br J Cancer. 119: 96-104

Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death.

Eur Urol. 71: 740-747

Germline DNA-repair gene mutations and outcomes in men with metastatic castration-resistant prostate cancer receiving first-line abiraterone and enzalutamide.

Eur Urol. 74: 218-225

Platinum-based chemotherapy in metastatic prostate cancer with DNA repair gene alterations.

JCO Precis Oncol. 4: 355-366

Genomic analysis of three metastatic prostate cancer patients with exceptional responses to carboplatin indicating different types of DNA repair deficiency.

Eur Urol. 75: 184-192Isaacsson Velho P. et al.

Efficacy of radium-223 in bone-metastatic castration-resistant prostate cancer with and without homologous repair gene defects.

Eur Urol. 76: 170-176van der Doelen M.J. et al.

Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer.

Eur J Cancer. 136: 16-24

Differential response to olaparib treatment among men with metastatic castration-resistant prostate cancer harboring BRCA1 or BRCA2 Versus ATM Mutations.

Eur Urol. 76: 452-458

Non-BRCA DNA damage repair gene alterations and response to the PARP Inhibitor rucaparib in metastatic castration-resistant prostate cancer: analysis from the Phase II TRITON2 Study.

Clin Cancer Res. 26: 2487-2496

ATM inhibitor KU-55933 induces apoptosis and inhibits motility by blocking GLUT1- mediated glucose uptake in aggressive cancer cells with sustained activation of Akt.

FASEB J. 35: e21264

ATM deficiency promotes progression of CRPC by enhancing Warburg effect.

Endocr Relat Cancer. 26: 59-71

Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian.

Cancer. 121: 269-275

Prevalence of Suspected Hereditary Cancer Syndromes and Germline Mutations Among a Diverse Cohort of Probands Reporting a Family History of Prostate Cancer: Toward Informing Cascade Testing for Men.

Eur Urol Oncol. 3: 291-297

Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.

J Clin Oncol. 31: 1748-1757

Germline BRCA mutations denote a clinicopathologic subset of prostate cancer.

Clin Cancer Res. 16: 2115-2121

Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer.

Eur Urol. 68: 186-193

Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study.

Eur Urol. 77: 24-35

PROREPAIR-B: a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer.

J Clin Oncol. 37: 490-503

The impact of a BRCA2 mutation on mortality from screen-detected prostate cancer.

Br J Cancer. 111: 1238-1240Edwards S.M. Cunningham S.A. Dunlop A.L. et al.

Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis.

Br J Cancer. 103: 918-924Thorne H. Willems A.J. Niedermayr E. et al.

Decreased prostate cancer-specific survival of men with BRCA2 mutations from multiple breast cancer families.

Cancer Prev Res (Phila). 4: 1002-1010Tryggvadóttir L. Vidarsdóttir L. Thorgeirsson T. et al.

Prostate cancer progression and survival in BRCA2 mutation carriers.

J Natl Cancer Inst. 99: 929-935Nyberg T. Frost D. Barrowdale D. et al.

Prostate cancer risk by BRCA2 genomic regions.

Eur Urol. 78: 494-497Cheng H.H. Pritchard C.C. Boyd T. et al.

Biallelic inactivation of brca2 in platinum-sensitive metastatic castration-resistant prostate cancer.

Eur Urol. 69: 992-995Mateo J. Porta N. Bianchini D. et al.

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.

Lancet Oncol. 21: 162-174Abida W. Patnaik A. Campbell D. et al.

Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration.

J Clin Oncol. 38: 3763-3772Clarke N. Wiechno P. Alekseev B. et al.

Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.

Lancet Oncol. 19: 975-986Schiewer M.J. Mandigo A.C. Gordon N. et al.

PARP-1 regulates DNA repair factor availability.

EMBO Mol Med. 10: e8816Mainetti L.E. Zhe X. Diedrich J. et al.

Bone-induced c-kit expression in prostate cancer: a driver of intraosseous tumor growth.

Int J Cancer. 136: 11-20Moro L. Arbini A.A. Yao J.L. et al.

Loss of BRCA2 promotes prostate cancer cell invasion through up-regulation of matrix metalloproteinase-9.

Cancer Sci. 99: 553-563Risbridger G.P. Taylor R.A. Clouston D. et al.

Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis.

Eur Urol. 67: 496-503Porter L.H. Hashimoto K. Lawrence M.G. et al.

Intraductal carcinoma of the prostate can evade androgen deprivation, with emergence of castrate-tolerant cells.

BJU Int. 121: 971-978Goodwin J.F. Schiewer M.J. Dean J.L. et al.

A hormone-DNA repair circuit governs the response to genotoxic insult.

Cancer Discov. 3: 1254-1271Polkinghorn W.R. Parker J.S. Lee M.X. et al.

Androgen receptor signaling regulates DNA repair in prostate cancers.

Cancer Discov. 3: 1245-1253Schiewer M.J. Goodwin J.F. Han S. et al.

Dual roles of PARP-1 promote cancer growth and progression.

Cancer Discov. 2: 1134-1149Schiewer M.J. Knudsen K.E.

Linking DNA Damage and Hormone Signaling Pathways in Cancer.

Trends Endocrinol Metab. 27: 216-225Annala M. Struss W.J. Warner E.W. et al.

Treatment outcomes and tumor loss of heterozygosity in germline DNA repair- deficient prostate cancer.

Eur Urol. 72: 34-42Mateo J. Cheng H.H. Beltran H. et al.

Clinical outcome of prostate cancer patients with germline DNA repair mutations: retrospective analysis from an international study.

Eur Urol. 73: 687-693